Poly(lactic-co-glycolic acid) nanoparticle-mediated interleukin-12 delivery for the treatment of diabetic retinopathy

Lina Zeng,1,* Wenbei Ma,1,* Lingyu Shi,1 Xiaohong Chen,1 Rong Wu,1 Yingying Zhang,2 Huaiwen Chen,2 Hui Chen11Department of Ophthalmology, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, People’s Republic of China; 2Sunlipo Biotech Research Center for Nanomedicine, Shangha...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Zeng L, Ma W, Shi L, Chen X, Wu R, Zhang Y, Chen H
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2019
Materias:
Acceso en línea:https://doaj.org/article/42dfc19cb6d44749bc298306008df7c5
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:42dfc19cb6d44749bc298306008df7c5
record_format dspace
spelling oai:doaj.org-article:42dfc19cb6d44749bc298306008df7c52021-12-02T10:44:55ZPoly(lactic-co-glycolic acid) nanoparticle-mediated interleukin-12 delivery for the treatment of diabetic retinopathy1178-2013https://doaj.org/article/42dfc19cb6d44749bc298306008df7c52019-08-01T00:00:00Zhttps://www.dovepress.com/polylactic-co-glycolic-acid-nanoparticle-mediated-interleukin-12-deliv-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Lina Zeng,1,* Wenbei Ma,1,* Lingyu Shi,1 Xiaohong Chen,1 Rong Wu,1 Yingying Zhang,2 Huaiwen Chen,2 Hui Chen11Department of Ophthalmology, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, People’s Republic of China; 2Sunlipo Biotech Research Center for Nanomedicine, Shanghai 201507, People’s Republic of China*These authors contributed equally to this workBackground: Diabetic retinopathy (DR) is a complication of diabetes that affects the eyes and vision. It is a leading cause of visual impairment and blindness in working-age people. Vascular endothelial growth factor-A (VEGF-A) is a primary initiator and potential mediator of DR. Matrix metalloproteinase-9 (MMP-9) plays a progressive role in the onset and severity of DR. Interleukin-12 (IL-12) is a cytokine of the chemokine family that could reduce the levels of MMP-9 and VEGF-A and suppress tumor angiogenesis. We hypothesize that IL-12 may also have superior therapeutic efficacy against DR. However, protein drugs are prone to degradation by various proteases after drug injection. Therefore, they have short half-lives and low blood concentrations. The objective of this study was to develop IL-12-loaded nanoparticles for long-term and sustained DR treatment.Methods: IL-12-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles (IL-12-PNP) were developed by double emulsion. The characteristics, anti-DR activity, and mechanisms of IL-12-PNP were examined in vitro and in vivo.Results: The nanoparticles had suitable particle size (∼132.8 nm), drug encapsulation efficiency (∼34.7%), and sustained drug release profile. Compared with IL-12 and blank nanoparticles, IL-12-PNP showed better inhibitory efficacy against VEGF-A and MMP-9 expression in rat endothelial cells and DR mouse retina. Intraocular IL-12-PNP administration significantly reduced retinal damage in DR mice as they presented with increased thickness and decreased neovascularization after treatment.Conclusion: These data indicate that IL-12-PNP is an effective drug delivery platform for DR therapy. It restores the thickness and reduces neovascularization of the retinas of DR mice.Keywords: interleukin-12, nanoparticles, angiogenesis, controlled release, diabetic retinopathyZeng LMa WShi LChen XWu RZhang YChen HChen HDove Medical Pressarticleinterleukin-12nanoparticlesangiogenesiscontrolled releasediabetic retinopathyMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 14, Pp 6357-6369 (2019)
institution DOAJ
collection DOAJ
language EN
topic interleukin-12
nanoparticles
angiogenesis
controlled release
diabetic retinopathy
Medicine (General)
R5-920
spellingShingle interleukin-12
nanoparticles
angiogenesis
controlled release
diabetic retinopathy
Medicine (General)
R5-920
Zeng L
Ma W
Shi L
Chen X
Wu R
Zhang Y
Chen H
Chen H
Poly(lactic-co-glycolic acid) nanoparticle-mediated interleukin-12 delivery for the treatment of diabetic retinopathy
description Lina Zeng,1,* Wenbei Ma,1,* Lingyu Shi,1 Xiaohong Chen,1 Rong Wu,1 Yingying Zhang,2 Huaiwen Chen,2 Hui Chen11Department of Ophthalmology, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, People’s Republic of China; 2Sunlipo Biotech Research Center for Nanomedicine, Shanghai 201507, People’s Republic of China*These authors contributed equally to this workBackground: Diabetic retinopathy (DR) is a complication of diabetes that affects the eyes and vision. It is a leading cause of visual impairment and blindness in working-age people. Vascular endothelial growth factor-A (VEGF-A) is a primary initiator and potential mediator of DR. Matrix metalloproteinase-9 (MMP-9) plays a progressive role in the onset and severity of DR. Interleukin-12 (IL-12) is a cytokine of the chemokine family that could reduce the levels of MMP-9 and VEGF-A and suppress tumor angiogenesis. We hypothesize that IL-12 may also have superior therapeutic efficacy against DR. However, protein drugs are prone to degradation by various proteases after drug injection. Therefore, they have short half-lives and low blood concentrations. The objective of this study was to develop IL-12-loaded nanoparticles for long-term and sustained DR treatment.Methods: IL-12-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles (IL-12-PNP) were developed by double emulsion. The characteristics, anti-DR activity, and mechanisms of IL-12-PNP were examined in vitro and in vivo.Results: The nanoparticles had suitable particle size (∼132.8 nm), drug encapsulation efficiency (∼34.7%), and sustained drug release profile. Compared with IL-12 and blank nanoparticles, IL-12-PNP showed better inhibitory efficacy against VEGF-A and MMP-9 expression in rat endothelial cells and DR mouse retina. Intraocular IL-12-PNP administration significantly reduced retinal damage in DR mice as they presented with increased thickness and decreased neovascularization after treatment.Conclusion: These data indicate that IL-12-PNP is an effective drug delivery platform for DR therapy. It restores the thickness and reduces neovascularization of the retinas of DR mice.Keywords: interleukin-12, nanoparticles, angiogenesis, controlled release, diabetic retinopathy
format article
author Zeng L
Ma W
Shi L
Chen X
Wu R
Zhang Y
Chen H
Chen H
author_facet Zeng L
Ma W
Shi L
Chen X
Wu R
Zhang Y
Chen H
Chen H
author_sort Zeng L
title Poly(lactic-co-glycolic acid) nanoparticle-mediated interleukin-12 delivery for the treatment of diabetic retinopathy
title_short Poly(lactic-co-glycolic acid) nanoparticle-mediated interleukin-12 delivery for the treatment of diabetic retinopathy
title_full Poly(lactic-co-glycolic acid) nanoparticle-mediated interleukin-12 delivery for the treatment of diabetic retinopathy
title_fullStr Poly(lactic-co-glycolic acid) nanoparticle-mediated interleukin-12 delivery for the treatment of diabetic retinopathy
title_full_unstemmed Poly(lactic-co-glycolic acid) nanoparticle-mediated interleukin-12 delivery for the treatment of diabetic retinopathy
title_sort poly(lactic-co-glycolic acid) nanoparticle-mediated interleukin-12 delivery for the treatment of diabetic retinopathy
publisher Dove Medical Press
publishDate 2019
url https://doaj.org/article/42dfc19cb6d44749bc298306008df7c5
work_keys_str_mv AT zengl polylacticcoglycolicacidnanoparticlemediatedinterleukin12deliveryforthetreatmentofdiabeticretinopathy
AT maw polylacticcoglycolicacidnanoparticlemediatedinterleukin12deliveryforthetreatmentofdiabeticretinopathy
AT shil polylacticcoglycolicacidnanoparticlemediatedinterleukin12deliveryforthetreatmentofdiabeticretinopathy
AT chenx polylacticcoglycolicacidnanoparticlemediatedinterleukin12deliveryforthetreatmentofdiabeticretinopathy
AT wur polylacticcoglycolicacidnanoparticlemediatedinterleukin12deliveryforthetreatmentofdiabeticretinopathy
AT zhangy polylacticcoglycolicacidnanoparticlemediatedinterleukin12deliveryforthetreatmentofdiabeticretinopathy
AT chenh polylacticcoglycolicacidnanoparticlemediatedinterleukin12deliveryforthetreatmentofdiabeticretinopathy
AT chenh polylacticcoglycolicacidnanoparticlemediatedinterleukin12deliveryforthetreatmentofdiabeticretinopathy
_version_ 1718396758721036288